Back to top
more

First Trust NASDAQ Pharmaceuticals ETF: (FTXH)

(Delayed Data from NASDAQ) As of Feb 27, 2026 01:20 PM ET

$35.57 USD

35.566
7,426

+0.50 (1.42%)

Volume: 7,426

Zacks ETF Rank

This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:

Zacks Rank Definition
1 Strong Buy
2 Buy
3 Hold
4 Sell
5 Strong Sell

See all the Top Ranked ETFs here - The complete list of all the top ranked ETFs

3 - Hold of 5     3    

After-Market: $35.56 -0.01 (-0.02 %) 7:58 PM ET

Zacks News

Sweta Jaiswal, FRM headshot

What Lies Ahead for Pfizer ETFs After Another Round of Upbeat Vaccine Data

Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in the coronavirus vaccine development.

Sanghamitra Saha headshot

3 Reasons to Bet on Healthcare ETFs

The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.

Sweta Killa headshot

Q3 Earnings Fail to Impress Pharma ETFs

The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.

Sweta Jaiswal, FRM headshot

Nasdaq Pharmaceuticals ETF (FTXH) Hits a 52-Week High

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) has hit a new 52-week high. Are more gains in store?

Sweta Killa headshot

Pharma ETFs Soar on Robust Q2 Earnings

Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.

Sanghamitra Saha headshot

COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries

There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.

Sweta Killa headshot

Pharma ETFs Gain on Healthy Q4 Earnings

Strong results led to solid trading in pharma ETFs over the past week.

Sweta Killa headshot

Pharma ETFs Set to Benefit Post Strong Q3 Earnings

Robust results led to solid trading in pharma ETFs in a month.

Sweta Killa headshot

Pharma Q2 Earnings Growth Highest: Time to Buy ETFs?

Despite robust results, pharma ETFs have been trending downward in a month.

Sweta Killa headshot

Pharma ETFs Down Despite Solid Q1 Results

Despite such robust results, pharma ETFs have been trending downward in a month.